Skip to content

Artificial Fractional Carbon Dioxide Laser Treatment of Xanthelasma

Clinical efficacy and safety of Artificial Fractional Carbon Dioxide Laser Treatment of Xanthelasma

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500099773
Enrollment
Unknown
Registered
2025-03-28
Start date
2025-04-01
Completion date
Unknown
Last updated
2025-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Xanthelasma Palpebrarum

Interventions

control side:Dot matrix CO2 laser therapy
intervention side:Artificial dot matrix CO2 laser therapy

Sponsors

Dematology Hospital of Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Age > 18 years, < 65 years; 2. It met the diagnostic criteria of xanthoma and the lesions were bilateral symmetrical; 3. Agree to cooperate with the completion of treatment and follow-up visits, and agree to sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Medical history/surgical history of any clinical systemic disease that is out of control and serious or may affect treatment and effectiveness evaluation, such as circulatory system, nervous system, blood system, immune system, psychiatric system, etc. 2. Lesions and surrounding scars, congenital malformations and other appearance characteristics that are not conducive to observation and evaluation, or have previously undergone eye and periocular plastic surgery/repair, or related operations that will affect the normal structure of the eye skin; 3. Intraocular or skin infections and other active skin diseases; 4. Receiving other facial rejuvenation treatments or sun exposure with or without protective measures during treatment; 5. Participants who participated in or are participating in clinical trials of other interventional drugs or medical devices within 3 months prior to screening; 6. Received other phototherapy or oral isotretinoic acid, minocycline and other photosensitive drugs 3 months before screening; 7. The investigator believes that the subjects have other conditions that may affect their compliance or are not suitable to participate in the study; 8. Those who have a history of drug abuse, drug use or alcohol dependence before screening; 9. Subjects who were assessed by the study physician as unsuitable for enrollment.

Design outcomes

Secondary

MeasureTime frame
Reoccurrence rate;complications;Patient satisfaction;

Primary

MeasureTime frame
clearance rate;

Countries

China

Contacts

Public ContactLiu Zhenfeng

Dematology Hospital of Southern Medical University

liuzhenfengpuma@163.com+86 20 83027579

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026